Topiramate nella terapia di profilassi dell'emicrania

Translated title of the contribution: Topiramate as prophylactic treatment in migraine

G. Di Trapani, D. Mei, C. Marra, S. Mazza, A. Capuano

Research output: Contribution to journalArticle

Abstract

Topiramate is a novel antiepileptic drug (AED) which exerts its action through (1) blocking of voltage gated sodium channel, (2) increase of GABAergic activity through stimulation of the non benzodiazepine site of the GABAA receptors, (3) antagonising the glutamate kainate/AMPA receptor. After an observation period of 4 weeks during which subjects reported the frequency and severity of migraine attacks, we have conducted in a 3 months study evaluating the effectiveness and safety of topiramate used as prophylaxis of migraine attacks in 20 patients selected according to the IHS criteria. No patient interrupted the study and topiramate resulted well tolerated; adverse events (dizziness, ataxia, paresthesia, disartria) were mostly transitory and of mild to moderate severity. The preliminary results of this study reveal a significant reduction in the frequency of attacks in the study sample. Although the number of study participants was too low to enable definite conclusions, the results suggest that topiramate represents an interesting candidate for future placebo controlled studies, and that this drug could feature a valid alternative to traditional anti-migraine prophylactic agents.

Original languageItalian
Pages (from-to)164-168
Number of pages5
JournalActa Medica Romana
Volume38
Issue number1-2
Publication statusPublished - 2000

Fingerprint

Migraine Disorders
Voltage-Gated Sodium Channels
Kainic Acid Receptors
AMPA Receptors
Paresthesia
Dizziness
GABA-A Receptors
Ataxia
Therapeutics
Benzodiazepines
Anticonvulsants
Glutamic Acid
Placebos
Observation
Safety
topiramate
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Di Trapani, G., Mei, D., Marra, C., Mazza, S., & Capuano, A. (2000). Topiramate nella terapia di profilassi dell'emicrania. Acta Medica Romana, 38(1-2), 164-168.

Topiramate nella terapia di profilassi dell'emicrania. / Di Trapani, G.; Mei, D.; Marra, C.; Mazza, S.; Capuano, A.

In: Acta Medica Romana, Vol. 38, No. 1-2, 2000, p. 164-168.

Research output: Contribution to journalArticle

Di Trapani, G, Mei, D, Marra, C, Mazza, S & Capuano, A 2000, 'Topiramate nella terapia di profilassi dell'emicrania', Acta Medica Romana, vol. 38, no. 1-2, pp. 164-168.
Di Trapani G, Mei D, Marra C, Mazza S, Capuano A. Topiramate nella terapia di profilassi dell'emicrania. Acta Medica Romana. 2000;38(1-2):164-168.
Di Trapani, G. ; Mei, D. ; Marra, C. ; Mazza, S. ; Capuano, A. / Topiramate nella terapia di profilassi dell'emicrania. In: Acta Medica Romana. 2000 ; Vol. 38, No. 1-2. pp. 164-168.
@article{b372a43e02874d6a8f1ccc051028e4c7,
title = "Topiramate nella terapia di profilassi dell'emicrania",
abstract = "Topiramate is a novel antiepileptic drug (AED) which exerts its action through (1) blocking of voltage gated sodium channel, (2) increase of GABAergic activity through stimulation of the non benzodiazepine site of the GABAA receptors, (3) antagonising the glutamate kainate/AMPA receptor. After an observation period of 4 weeks during which subjects reported the frequency and severity of migraine attacks, we have conducted in a 3 months study evaluating the effectiveness and safety of topiramate used as prophylaxis of migraine attacks in 20 patients selected according to the IHS criteria. No patient interrupted the study and topiramate resulted well tolerated; adverse events (dizziness, ataxia, paresthesia, disartria) were mostly transitory and of mild to moderate severity. The preliminary results of this study reveal a significant reduction in the frequency of attacks in the study sample. Although the number of study participants was too low to enable definite conclusions, the results suggest that topiramate represents an interesting candidate for future placebo controlled studies, and that this drug could feature a valid alternative to traditional anti-migraine prophylactic agents.",
author = "{Di Trapani}, G. and D. Mei and C. Marra and S. Mazza and A. Capuano",
year = "2000",
language = "Italian",
volume = "38",
pages = "164--168",
journal = "Acta Medica Romana",
issn = "0001-6098",
publisher = "Vita e Pensiero",
number = "1-2",

}

TY - JOUR

T1 - Topiramate nella terapia di profilassi dell'emicrania

AU - Di Trapani, G.

AU - Mei, D.

AU - Marra, C.

AU - Mazza, S.

AU - Capuano, A.

PY - 2000

Y1 - 2000

N2 - Topiramate is a novel antiepileptic drug (AED) which exerts its action through (1) blocking of voltage gated sodium channel, (2) increase of GABAergic activity through stimulation of the non benzodiazepine site of the GABAA receptors, (3) antagonising the glutamate kainate/AMPA receptor. After an observation period of 4 weeks during which subjects reported the frequency and severity of migraine attacks, we have conducted in a 3 months study evaluating the effectiveness and safety of topiramate used as prophylaxis of migraine attacks in 20 patients selected according to the IHS criteria. No patient interrupted the study and topiramate resulted well tolerated; adverse events (dizziness, ataxia, paresthesia, disartria) were mostly transitory and of mild to moderate severity. The preliminary results of this study reveal a significant reduction in the frequency of attacks in the study sample. Although the number of study participants was too low to enable definite conclusions, the results suggest that topiramate represents an interesting candidate for future placebo controlled studies, and that this drug could feature a valid alternative to traditional anti-migraine prophylactic agents.

AB - Topiramate is a novel antiepileptic drug (AED) which exerts its action through (1) blocking of voltage gated sodium channel, (2) increase of GABAergic activity through stimulation of the non benzodiazepine site of the GABAA receptors, (3) antagonising the glutamate kainate/AMPA receptor. After an observation period of 4 weeks during which subjects reported the frequency and severity of migraine attacks, we have conducted in a 3 months study evaluating the effectiveness and safety of topiramate used as prophylaxis of migraine attacks in 20 patients selected according to the IHS criteria. No patient interrupted the study and topiramate resulted well tolerated; adverse events (dizziness, ataxia, paresthesia, disartria) were mostly transitory and of mild to moderate severity. The preliminary results of this study reveal a significant reduction in the frequency of attacks in the study sample. Although the number of study participants was too low to enable definite conclusions, the results suggest that topiramate represents an interesting candidate for future placebo controlled studies, and that this drug could feature a valid alternative to traditional anti-migraine prophylactic agents.

UR - http://www.scopus.com/inward/record.url?scp=0033676902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033676902&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0033676902

VL - 38

SP - 164

EP - 168

JO - Acta Medica Romana

JF - Acta Medica Romana

SN - 0001-6098

IS - 1-2

ER -